Excited to share our multi-institutional study on ALK+ Large B-cell lymphoma in @AjHematology :
Outcomes remain poor with intensified chemo and consolidative ASCT. Select durable remissions occurred with biologically targeted therapies & allo-SCT
onlinelibrary.wiley.com/doi/10.1002/aj…
onlinelibrary.wiley.com Multi‐Institutional Study of ALK‐Positive Large B‐Cell Lymphoma: Outcomes in the Era of ALK... In this multi-center cohort of 39 patients with anaplastic lymphoma kinase–positive large B-cell lymphoma (ALK+ LBCL), median overall survival (OS) was 1.5 years and median event-free survival (EFS)... Outcomes remain poor with intensified chemo and consolidative ASCT. Select durable remissions occurred with biologically targeted therapies & allo-SCT
onlinelibrary.wiley.com/doi/10.1002/aj…